The Food & Drug Administration announced Friday that its committee on vaccines will meet Dec. 10th to review Pfizer's request for emergency use authorization (EUA) of its Covid-19 vaccine.
This comes two days after Pfizer, with their German partner BioNTech, released promising final results that show their vaccine is 95% effective and protects elderly adults who are most at risk of dying. Pfizer had submitted the EUA request earlier in the day Friday.
An FDA spokesperson told FOX Business the three-week window is necessary because "this amount of time will allow the FDA to thoroughly evaluate the data and information submitted in the EUA request before the meeting.
This comes two days after Pfizer, with their German partner BioNTech, released promising final results that show their vaccine is 95% effective and protects elderly adults who are most at risk of dying. Pfizer had submitted the EUA request earlier in the day Friday.
An FDA spokesperson told FOX Business the three-week window is necessary because "this amount of time will allow the FDA to thoroughly evaluate the data and information submitted in the EUA request before the meeting.
I was hoping for faster.
No comments:
Post a Comment